Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04868968 · ClinicalTrials.gov registry record · Phase 2
Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS)
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT04868968 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 4 participants.
The verdict
NCT04868968, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this phase II study was to assess the safety, tolerability and efficacy of DFV890 in participants with FCAS.
Interventions
- DRUG DFV890
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2021-09-20 |
| Est. Completion | 2023-05-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04868968
The ClinicalTrials.gov registry entry for NCT04868968 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DFV890 is the first listed.
NCT04868968 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04868968 about?
NCT04868968 is a clinical study titled "Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS)". The purpose of this phase II study was to assess the safety, tolerability and efficacy of DFV890 in participants with FCAS.
What is the current status of trial NCT04868968?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2021-09-20. Estimated completion is 2023-05-05.
What interventions are being tested in trial NCT04868968?
The interventions under investigation include: DFV890 (DRUG).
Who is sponsoring clinical trial NCT04868968?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.